Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $47.14

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $47.00.

Several research firms recently issued reports on FDMT. Leerink Partners restated an “outperform” rating and issued a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. BMO Capital Markets cut their target price on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, July 18th. Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. lifted its stake in shares of 4D Molecular Therapeutics by 21.3% in the first quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company’s stock valued at $160,941,000 after buying an additional 888,300 shares in the last quarter. Janus Henderson Group PLC boosted its stake in 4D Molecular Therapeutics by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 3,197,444 shares of the company’s stock valued at $101,844,000 after purchasing an additional 104,148 shares during the last quarter. Vanguard Group Inc. boosted its stake in 4D Molecular Therapeutics by 25.3% during the 1st quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company’s stock valued at $74,551,000 after purchasing an additional 473,094 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in 4D Molecular Therapeutics by 238.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after purchasing an additional 1,087,147 shares in the last quarter. Finally, Novo Holdings A S raised its stake in shares of 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $8.02 on Tuesday. 4D Molecular Therapeutics has a 52 week low of $7.32 and a 52 week high of $36.25. The firm’s fifty day moving average is $10.58 and its 200-day moving average is $17.31. The firm has a market cap of $416.80 million, a P/E ratio of -3.49 and a beta of 2.82.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.